In a first approach, we analyzed the expression levels of HOTAIR in grades II and III gliomas, and in grade IV GBM patients using gene expression microarray data and RNA-sequencing (RNA-seq) data from The Cancer Genome Atlas (TCGA). This evidence concerns the gene HOTAIR and central nervous system cancer.